The c-Myc oncoprotein is strongly implicated in B-cell neoplasms such as human Burkitt lymphomas and mouse plasmocytomas. Transgenic mice in which the myc gene is juxtaposed to an immunoglobulin enhancer (Em-myc) also develop B-cell lymphomas, but relatively late in life. In addition, these neoplasms are invariably clonal, suggesting the involvement of additional mutations. Such mutations frequently aect the p53 tumour suppressor gene or its positive regulator Arf, hinting that inactivation of the p53 pathway might be the second hit required for the progression towards malignancy. However, even tumours arising in Em-myc/Arf-null animals are thought to be clonal. This observation raised doubts whether overexpression of Myc in p53-null B-cell precursors is sucient for tumorigenesis. To address this question, we have established a new, non-transgenic mouse model of B-lymphoma. This model is based on isolation of primary bone marrow (BM) cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic. Predictably, wild type BM cells infected in vivo by LMycSN were not tumorigenic. However, LMycSN-infected p53-null BM cells readily gave rise to B-cell lymphomas composed predominantly of late pro-B/small pre-B-cells. In these tumours, heavy chain gene rearrangements were analysed using two independent PCR-based assays. All neoplasms with DJrearrangements were found to be polyclonal. This result suggests that inactivation of p53 and overexpression of Myc is all that is necessary for the development of fulledged B-lymphomas. Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes.
The c-Myc oncoprotein is strongly implicated in B-cell neoplasms such as human Burkitt lymphomas and mouse plasmocytomas. Transgenic mice in which the myc gene is juxtaposed to an immunoglobulin enhancer (Em-myc) also develop B-cell lymphomas, but relatively late in life. In addition, these neoplasms are invariably clonal, suggesting the involvement of additional mutations. Such mutations frequently aect the p53 tumour suppressor gene or its positive regulator Arf, hinting that inactivation of the p53 pathway might be the second hit required for the progression towards malignancy. However, even tumours arising in Em-myc/Arf-null animals are thought to be clonal. This observation raised doubts whether overexpression of Myc in p53-null B-cell precursors is sucient for tumorigenesis. To address this question, we have established a new, non-transgenic mouse model of B-lymphoma. This model is based on isolation of primary bone marrow (BM) cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic. Predictably, wild type BM cells infected in vivo by LMycSN were not tumorigenic. However, LMycSN-infected p53-null BM cells readily gave rise to B-cell lymphomas composed predominantly of late pro-B/small pre-B-cells. In these tumours, heavy chain gene rearrangements were analysed using two independent PCR-based assays. All neoplasms with DJrearrangements were found to be polyclonal. This result suggests that inactivation of p53 and overexpression of Myc is all that is necessary for the development of fulledged B-lymphomas. Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes. Oncogene (2002 ) 21, 1922 ± 1927 . DOI: 10.1038 Keywords: Myc; p53; B-lymphoma; immunoglobulins; gene rearrangement c-myc is an oncogene whose involvement in haematopoietic tumours is well-documented but incompletely understood. It was reported two decades ago that murine and human B-lymphomas often overexpress Myc. This is due to chromosomal translocations juxtaposing Myc and one of the immunoglobulin loci that are transcriptionally active in B-cells (Shen-Ong et al., 1982; Taub et al., 1982; Dalla-Favera et al., 1982) . For example, the hallmark of human Burkitt lymphoma (BL) is the (8;14) translocation that subjects c-myc to the control of the m heavy chain gene enhancer (Dalla-Favera et al., 1983) . To con®rm the role of Myc in lymphomagenesis, transgenic mice have been generated in which c-myc expression is controlled by various immunoglobulin promoters. Such animals inevitably succumb to B-cell neoplasms (Adams et al., 1985; Schmidt et al., 1988; Kovalchuk et al., 2000) . In the ®rst and the best studied model (Em-myc), animals developed lymphomas accompanied by lymphoblastoid leukaemia within the ®rst year of life (Harris et al., 1988) . However, malignant cells were not detectable in young animals and tumours arising in subsequent months were clonal in nature (Langdon et al., 1986) . BL and other non-Hodgkin lymphomas (NHL) are also invariably clonal (Pelicci et al., 1986) . This suggests that before full-¯edged tumours can develop, at least one and possibly more genetic alterations must occur .
Several events can cooperate with Myc during lymphomagenesis, such as infection by the Epstein ± Barr virus (Zimber-Strobl et al., 1999; Kulwichit et al., 1998; Wilson et al., 1996) and activation of bcl-1 (Lovec et al., 1994) or bcl-2 (Pegoraro et al., 1984; Strasser et al., 1990; Fanidi et al., 1992) . However, the one protein most consistently implicated in Mycinduced lymphomagenesis is p53. The corresponding gene is frequently mutated in AIDS-related (Bower, 2001 ) and other NHL with Myc overexpression (Newcomb, 1995; Klein, 1993) . Moreover, lymphomas in mice arise much sooner when the Em-myc transgene is combined with heterozygocity for p53, and resultant tumours often lose the remaining allele of this tumour suppressor (Hsu et al., 1995) .
An apparent requirement for p53 inactivation is likely to stem from the propensity of Myc to induce p53-dependent apoptosis (reviewed in Evan and Vousden, 2001; Prendergast, 1999) . This process is thought to involve activation of Arf (Zindy et al., 1998) , which positively regulates p53 at least in part via neutralization of its negative regulator Mdm-2 (Sherr and Weber, 2000) . Thus, even when wild type p53 is retained, the corresponding pathway might still be compromised via mutations aecting ARF. Indeed, such mutations could be readily found in Em-mycinduced lymphomas (Schmitt et al., 1999; Eischen et al., 1999; Jacobs et al., 1999) . Based on these data, inactivation of p53 is considered to be the second hit required for progression of Myc-overexpressing hyperproliferative cells towards malignancy.
This scenario is lent credence by the fact that the transforming potential of Myc is much better realized in p53-null cells. In wild-type mouse embryo ®broblasts (MEF), over-expression of Myc leads to either G 2 arrest (Felsher et al., 2000) or apoptosis (Zindy et al., 1998) . In p53-null MEF both processes are mitigated, and enhanced growth ensues. However, for tumorigenic conversion Myc-overexpressing MEF still require co-activation of Ras (Land et al., 1983) . In addition, ®broblasts are not natural targets for transforming Myc because Myc is not implicated in tumours of connective tissues, as it is in lymphomas. Myc-overexpressing IL-7-dependent B-cells also grow much more vigorously when the p53 pathway is inactivated (Eischen et al., 1999) . Still, apoptosis in these cells is attenuated but not completely suppressed (Hsu et al., 1995; Eischen et al., 1999) . Moreover, B-lymphomas arising in Em-myc/ARF-null mice appear to be clonal. Thus, it has been proposed that concomitant activation of Bcl-2 or Bcl-X L might be the third event involved in lymphomagenesis (Eischen et al., 2001) . While the signi®cance of mutations in bcl-2 and other genes has been recognized, it is unclear whether they are absolutely required for neoplastic growth or merely selected for during late stages of tumour progression. Thus, we set out to determine whether Myc-overexpressing, p53-null B-cell precursors are immediately tumorigenic in syngeneic mice.
This question could not be addressed using established lines because immortalization itself relies on distinct genetic events (Serrano et al., 1997) . To circumvent this problem, we isolated fresh bone marrows (BM) from femurs of 53-null mice (Jacks et al., 1994) and admixed dispersed organs with GP+E86 packaging cells (Markowitz et al., 1988) producing the Myc-encoding retrovirus LMycSN (Blackwood et al., 1994) . We have previously shown that the use of packaging cells instead of viral supernatants leads to higher rates of infection in vivo (Yu and ThomasTikhonenko, 2001 ). Admixed cells were subcutaneously injected, without prior culturing, in C57BL6 mice with which BM but not packaging cells were syngeneic. As controls, the`empty' retroviral vector LXSN and BMs from wild-type mice were used. Four to ®ve weeks later, ®ve out of ®ve mice injected with p53-null, LMycSN-infected BM cells developed tumours, while none of the animals in the other three groups did, even after 3 months of observation. Identical results were obtained in two more independent experiments (Table  1 and data not shown). To con®rm that these tumours were arising from LMycSN-infected and not spontaneously transformed cells, we performed both DNA Figure 1 Detection of proviral DNA (A) and RNA (B) in LMycSN-induced neoplasms. 1, 2, 3, 5, and 7 refer to individual tumours. Nucleic acids were extracted from dispersed tissues using TRI-reagent (Sigma, St. Louis, MO, USA). RNA was converted into cDNA using an RT ± PCR kit from GIBCO ± BRL (Grand Island, NY, USA). Reactions were performed both in the absence (7) and in the presence (+) of reverse transcriptase (RT). Genomic DNAs and cDNAs were subjected to 34 cycles of PCR using the following primers: TTGTACACCCTAA-GCCTCCG (sense, gag gene) and TGCTGCTGGTA-GAAGTTCTC (anti-sense; myc gene). PCR conditions were as follows: denaturation at 948C for 45 s, annealing at 648C for 45 s, extension at 728C for 60 s. Genomic DNA from primary spleenocytes and cDNA from the macrophage cell line I21 were used as negative controls. The LMycSN plasmid was used as a positive control. Migration of molecular weight markers (100 bp ladder, GIBCO ± BRL) is shown in the leftmost lanes and RT ± PCR using primers designed to amplify the gag-myc junction in the LMycSN provirus. As evidenced by the data presented in Figure 1A , B, all ®ve tumours tested in this experiment contained integrated LMycSN proviruses ( Figure 1A ) which were transcribed into RNA ( Figure 1B) . To characterize the origin of arising tumours and to rule out that packaging cells were contributing to these neoplasms, the latter were excised and subjected to histopathological staining. They were found to be composed exclusively of haematopoietic cells, with no ®broblastoid or stromal cells being evident. These tumours were well-vascularized (Figure 2A, arrows) , consistent with the propensity of Myc to induce angiogenesis (Ngo et al., 2000; Brandvold et al., 2000; Pelengaris et al., 1999) . Additionally, microscopic examination revealed numerous mitotic cells ( Figure  2A , circled) and the absence of identi®able plasma cells. These characteristics were consistent with LMycSN-induced tumours being lymphomas. To determine whether these neoplasms were T-or Blymphomas, tumour cells were also stained with several antibodies speci®c for B-lymphocytes (anti-CD45R, -CD19, and -surface IgM), T-lymphocytes (antiThy1.2, -CD4, and -CD8), as well as cells of monocyte/macrophage lineage (F4/80, CD11b) and leukocytes (anti-CD43). All tumours analysed were stained only with B-cell-reactive antibodies. They were strongly positive for CD19 and CD45R, weakly positive for CD43, and negative for surface IgM ( Figure 2B and data not shown). Identical staining patterns were observed with all other primary tumours. Furthermore, we checked whether LMycSN-induced Blymphomas were expressing recombination activating gene 1 (Rag-1) and terminal deoxynucleotidyl transferase (TdT). RT ± PCR analyses presented in Figure 2C , D revealed that all the tumours expressed the former but not the latter. This and low levels of CD43 are characteristic of late pro-B/small pre-B-cells, or stages Figure 1) . 406magni®cation is shown. Arrows point at blood vessels, and mitotic cells are circled. Prior to sectioning, tissues were ®xed in 10% neutral buered-formalin and embedded in paran. (B) FACS analysis of lineage markers on the surface of the same tumour. A single-cell suspension was obtained and live cells were stained with an indicated FITC-or PE-conjugated antibody. Antibodies against CD45R (B220), CD19, CD43, surface IgM, CD11b (Mac-1), and Thy1.2 were purchased from BD PharMingen (San Diego, CA, USA). Antibodies against CD4, CD8, and the F4/80 antigen were a kind gift from Dr Christopher Hunter (University of Pennsylvania). Samples were analysed using a FACScalibur¯ow cytometer and the CELLQuest software (Becton-Dickinson, Mountain View, CA, USA). (C,D) RT± PCR analyses of Rag-1 and TdT expression in LMycSN-induced neoplasms. cDNA samples were prepared as described in Figure 1 and subjected to PCR with the following pairs of primers: TGCAGACATTCTAGCACTCTGG and ACATCTGCCTT-CACGTCGAT (Rag-1; sense and antisense, respectively) and GAAGATGGGAACAACTCGAAGAG and CAGGTGCTG-GAACATTCTGGGAG (TdT; sense and antisense, respectively). cDNAs from the macrophage cell line I21 and primary thymocytes were used as a negative and a positive controls, respectively. PCR conditions were identical to those in Figure 1 , except that for Rag-1 PCR annealing temperature was lowered to 628C. Migration of molecular weight markers (100 bp ladder, GIBCO ± BRL) is shown in the leftmost lanes C/D per Hardy's nomenclature (Hardy et al., 1991; Li et al., 1993) . The derivation of tumours from immature B-cells has also been observed in Em-myc mice (Iritani and Eisenman, 1999) although some of Em-myc tumours were of more mature phenotype and positive for surface IgM (Adams et al., 1985) .
Given the relatively short latent period before tumours become palpable, we hypothesized that overexpression of Myc and inactivation of p53 is all that is necessary for B-cell transformation. To test this hypothesis, we assessed clonality of arising tumours. If additional genetic events are required for lymphomagenesis, LMycSN-induced B-lymphomas would be clonal. On the other hand, if overexpression of Myc combined with inactivation of p53 is sucient for lymphomagenesis, all infected cells could undergo neoplastic growth, resulting in polyclonal tumours. To distinguish between these two possibilities, we analysed rearrangements of D and J regions of the immunoglobulin heavy chain genes. DJ junctions were ampli®ed using PCR and the speci®city of resultant fragments was con®rmed using Southern blotting, as described by Hardy and co-authors (Li et al., 1993) . All lymphomas that were positive for DJ rearrangement clearly yielded multiple fragments (e.g., tumours Myc7 & Myc8 in Figure 3A , right panel). The pattern was similar to that seen with bona ®de polyclonal BM populations (left panel; a melanoma cell line was used as a negative control). However, since the primers used in this assay amplify 440 dierent DJ-fragments, precise identi®cation of DNA products was problematic. To circumvent this problem, we employed another set of nested PCR primers which was speci®c for the Q52 subset of D-regions and could thus yield only four discreet fragments: 1500 bp (D Q52 J H 1), 1190 bp (D Q52 J H 2), 770 bp (D Q52 J H 3), and 240 bp (D Q52 J H 4) (ten Boekel et al., 1995; Rolink et al., 1999) . When used on a DJ-rearranged DNA (e.g., Myc8), this set of primers readily ampli®ed all predicted fragments but the longest one ( Figure 3B ). The identities of all three PCR fragments were con®rmed by sequencing. The absence of the 1500 bp fragment could be attributed to preferential ampli®cation of shorter fragments in PCR reactions. We thus believe that LMycSN-induced B-cell lymphomas are truly polyclonal neoplasms.
Interestingly, we did not observe formation of Tlymphomas or other neoplasms of haematopoietic origin. This is not because Myc is intrinsically unable to transform T-cell precursors: infection with LMycSN of p53-null thymocytes does give rise to T-lymphomas (D Yu and A Thomas-Tikhonenko, unpublished observation). Furthermore, it has been reported earlier that intraperitoneal injection of a Myc-retrovirus could lead to the induction of monocytic tumours (Baumbach et al., 1986) . None of LMycSN-induced primary tumours express any macrophage markers, although one of them has been found to do so upon prolonged culturing in vitro (D Yu and A Thomas-Tikhonenko, manuscript in preparation). We thus believe that, of all haematopoietic cells in the BM, B-cell precursors are most susceptible to transformation by Myc.
Moreover, over-expression of Myc combined with p53 inactivation appears to suce for the formation of full-¯edged tumours. Our conclusion is somewhat unexpected in light of the observation that Blymphomas arising in Em-myc/ARF-null mice are clonal (Eischen et al., 2001) . This discrepancy could be explained in two ways. One is that in the Em-myc model (as well as in naturally occurring tumours) additional selective pressure is applied before malignant neoplasms become apparent and clinically . PCR conditions were as follows: denaturation at 948C for 45 s, annealing at 618C for 45 s, extension at 728C for 60 s (32 cycles). PCR products were separated in an agarose gel, transferred to a nylon membrane, and probed with the 32 P-labelled pJ11 probe. Genomic DNAs from bone marrow and the B16 melanoma were used as a positive and a negative controls, respectively. (B) Nested PCR analysis of DJ recombination. Genomic DNAs were subjected to PCR with primers designed to amplify four possible junctions between D-Q52 and J H regions. The primers for the ®rst round were: CACAGAGAATTCTCCATAGTTGATAGCTCAG (D H Q52-1; sense) and AGGCTCTGAGATCCCTAGACAG (J H 4-1; antisense). PCR conditions were as follows: denaturation at 958C for 1 min, annealing at 608C for 1 min, extension at 728C for 2.5 min (28 cycles). Two ml from each reaction were subjected to the second round of PCR using a pair of internal primers: GCCTCAGAATTCCTGTGGTCTCTGAC-TGGT (D H Q52-2; sense) and GGGTCTAGACTCTCAGCCG-GCTCCCTCAGGG (J H 4-2; antisense) PCR conditions were as follows: denaturation at 958C for 20 s, annealing at 608C for 1 min, extension at 728C for 2 min (35 cycles). Sizes and compositions of the resultant fragments are indicated on the left; their identities were con®rmed by sequencing. Migration of molecular weight markers (100 bp ladder, GIBCO ± BRL) is shown in the right lane Oncogene Myc transforms p53-null B-cell precursors in vivo D Yu and A Thomas-Tikhonenko relevant. Such a selection might not be in place when tumours are grown subcutaneously. An alternative explanation is that inactivation of Arf is not equivalent to inactivation of p53 (Sherr and Weber, 2000) , and that the latter could be up-regulated by Myc even in Arf-null cells necessitating additional mutations in apoptosis-related genes. This scenario raises additional questions whether mutations in the p53 pathway are absolutely necessary during lymphomagenesis, and whether activation of an anti-apoptotic gene such as bcl-2 could bypass this requirement. Our new, non-transgenic mouse model for B-cell lymphoma would be instrumental in testing this hypothesis. Instead of LMycSN, bi-cistronic retroviruses could be used that, in addition to Myc, encode cooperating oncoproteins or dominant-negative mutants of tumour suppressors. In vivo infection with a bicistronic virus (Schmitt et al., 2000; Pear et al., 1998) is not nearly as time-and eort-consuming as generation of two transgenic strains followed by cross-breeding. In addition, our model system could be used to rapidly assess transforming potentials of various Myc mutants in an in vivo setting and thus provide new insights into the function of this oncoprotein.
